Telmisartan and a Fixed Combination S-Amlodipine/Atorvastatin in the Treatment of Essential Hypertension: Experience and Prospects for Clinical Use

L.A. Mishchenko, Ye.P. Svishchenko, H.M. Bozhenko


The objective of the study is to assess antihypertensive efficacy of telmisartan and its impact on the activity of systemic inflammation and carbohydrate and lipid metabolism in patients with essential hypertension (EH). Materials and methods. The study involved 29 patients with EH stage I–II, degree 1–2, who after a 7-day non-drug period and after 6 months of telmisartan therapy underwent a comprehensive clinical examination, ambulatory blood pressure (BP) monitoring, determination of
C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α), parameters of carbohydrate (glucose, insulin, HOMA, glycated hemoglobin (HbA1C)) and lipid metabolism. Results. Monotherapy with telmisartan made it possible to achieve target BP in 75.6 % of patients; after 6 months of treatment, a decrease in systolic BP was 20 mmHg, in diastolic BP — 13 mmHg. The drug helped to restore the normal two-phase rhythm of BP in patients with its initial disturbances and to reduce variability in systolic BP at night. Discussion. Under the influence of telmisartan, there was an improvement in carbohydrate metabolism manifested by a significant decrease of basal insulinemia by 21.5 %, reduction in glucose levels from 5.5 ± 0.2 mmol/l to 5.3 ± 0.1 mmol/l (p = 0.04) and HbA1c from 5.6 ± 0.1 % to 5.4 ± 0.1 % (p = 0.04). Against the background of telmisartan use, the blood levels of triglycerides have decreased by 17 % (p = 0.03), there was a tendency to lower levels of total cholesterol and low-density lipoprotein cholesterol. It was found that telmisartan treatment reduces serum CRP level by 13.9 % (p = 0.04) and IL-6 by 36.4 % (p = 0.02), but does not affect the content of TNF-α in the blood of patients with EH. Conclusions. The findings indicate a high antihypertensive efficacy and favorable metabolic effects of telmisartan, as well as its ability to inhibit the activity of low-grade inflammation. The article also supports a combined use of telmisartan and a fixed combination S-amlodipine/atorvastatin in terms of improving the prognosis of patients with EH due to the synergy of antihypertensive and lipid-lowering potential and pleiotropic effects of these drugs, whose action is aimed at slowing the progression of EH and atherosclerosis.


essential hypertension; blood pressure; telmisartan; S-amlodipine/atorvastatin; systemic inflammation; carbohydrate metabolism; lipid profile.


Лутай М.И. Эффективность фиксированной комбинации S-амлодипина и аторвастатина у пациентов с высоким и очень высоким сердечно-сосудистым риском / М.И. Лутай, И.П. Голикова, А.Ф. Лысенко, В.В. Товстуха // Український кардіологічний журнал. — 2013. — № 2. — C. 86-94.

Воронков Л.Г. Ефективність і переносимість фіксованої комбінації S(–) амлодипін/аторвастатин у пацієнтів з артеріальною гіпертензією високого серцево-судинного ризику / Л.Г. Воронков, Л.П. Паращенюк, А.В. Ляшенко, Н.А. Ткач // Український медичний часопис. — 2013. — № 1. — С. 73-75.

Заремба Є.Х. Клінічна ефективність лікування хворих на артеріальну гіпертензію: фокус на покращення прогнозу / Є.Х. Заремба, О.М. Голик, О.В. Заремба-Федчишин // Практикуючий лікар. — 2012. — № 3. — С. 37-39.

Sever P.S. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial / P.S. Sever, B. Dahlóf, N.R. Poulter [et al.] // Lancet. — 2003. — Vol. 361. — P. 1149-1158.

Ridker P.M. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein / P.M. Ridker, E. Danielson, F. Fonseca [et al.] // N. Engl. J. Med. — 2008. — Vol. 359. — P. 2195-2207.

Yusuf S. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease / S. Yusuf, D. Phil., J. Bosch [et al.] // N. Engl. J. Med. — 2016. — Vol. 374. — P. 2021-2031.

Telmisartan, Ramipril, or both for patients of high risk of vascular events / S. Yusuf, P. Sleight, C. Anderson [et al.] // New Engl. J. Med. — 2008. — Vol. 358. — P. 1547-1559.

Takagi H. Telmisartan improves insulin sensitivity: A meta-analisys of randomized head-to-head trials / H. Takagi, T. Umemoto // Int. J. Cardiol. — 2012. — Vol. 156. — P. 92-96.

Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials / B. Williams, Y. Lacourcie`re, H. Schumacher [et al.] // J. Hum. Hypertens. — 2009. — Vol. 23. — P. 610-619.

Verdecchia P. Ambulatory blood pressure monitoring day-night dip and early-morning surge in blood pressure in hypertension prognostic implications / P. Verdecchia, F. Angeli, G. Mazzotta [et al.] // Hypertension. — 2012. — Vol. 60. — P. 34-42.

Identification of telmisartan as an unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity / S.C. Benson, H.A. Pershadsingh, C.I. Ho [et al.] // Hypertension. — 2004. — Vol. 43. — P. 993-1002.

Effects of telmisartan on hypertensive patients with dyslipidemia and insulin resistance / D. Xu, J. Liu, C. Ji [et al.] // J. Geriatr. Cardiol. — 2007. — Vol. 4. — P. 149-152.

Telmisartan as a metabolic sartan: the first meta — analisys of randomized control trials in metabolic syndrome / H. Takagi, M. Niva, Y. Mizuno [et al.] // J. Am. Society of Hypertens. — 2013. — Vol. 7. — P. 229-235.

Vanitha M. Effect of telmisartan on serum lipid profile in patients with hypertension and dyslipidemia / M. Vanitha, K. Vijayal // Int. J. Med. Res. Health Sci. — 2013. — Vol. 2. — P. 745-749.

Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome / I. Porto, L. Di Vito, G.L. De Maria [et al.] // Am. J. Cardiol. — 2009. — Vol. 103. — P. 1500-1505.

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus / S. Koulouris, P. Symeonides, K. Triantafyllou [et al.] // Am. J. Cardiol. — 2005. — Vol. 95 — P. 1386-1388.

Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis / Emerging Risk Factors Collaboration, S. Kaptoge, E. Di Angelantonio, G. Lowe // Lancet. — 2010. — Vol. 375. — P. 132-40.

Jamerson K. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-Risk patients / K. Jamerson, M.A. Weber, G.L. Bakris [et al.] // N. Engl. J. Med. — 2008. — Vol. 359. — P. 2417-2428.

Dahlf B. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // B. Dahlóf, P.S. Sever, N.R. Poulter [et al.] // Lancet. — 2005. — Vol. 366. — P. 895-906.

Sever P. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial / P. Sever, B. Dahlóf, N. Poulter // Eur. Heart J. — 2006. — Vol. 27. — P. 2982-2988.

White W.B. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension / W.B. White, T.W. Littlejohn, C.R. Majul [et al.] // Blood. Press. Monit. — 2010. — Vol. 15. — P. 205-212.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта